2026 G. David Roodman: Medicine Researcher – H-Index, Publications & Awards

Discipline name	D-Index	World Ranking	Current World Ranking	National Ranking	Current National Ranking	Publications	Citations
Medicine	92	11320	10641	5810	5374	357	30585

Research.com Recognitions

2012 - Fellow of the American Association for the Advancement of Science (AAAS)
Member of the Association of American Physicians
Member of the Association of American Physicians

Overview

G. David Roodman is affiliated with Indiana University in the United States. Their research spans the field of Medicine, with a primary focus on Oncology and Hematology, as well as related areas such as Molecular Biology, Radiology, Nuclear Medicine and Imaging, and Genetics.

The scientist's main research topics encompass:

Multiple Myeloma Research and Treatments
Bone health and treatments
Peptidase Inhibition and Analysis
CAR-T cell therapy research
Coagulation, Bradykinin, Polyphosphates, and Angioedema
Sphingolipid Metabolism and Signaling
Ubiquitin and proteasome pathways

G. David Roodman has contributed to several scientific papers, including:

Notch3 signaling between myeloma cells and osteocytes in the tumor niche promotes tumor growth and bone destruction (2022), published in Neoplasia
GFI1-Dependent Repression of SGPP1 Increases Multiple Myeloma Cell Survival (2022), published in Cancers
Mapping the High-Risk Multiple Myeloma Cell Surface Proteome Identifies T-Cell Inhibitory Receptors for Immune Targeting (2021), published in Blood
A novel CCL3-HMGB1 signaling axis regulating osteocyte RANKL expression in multiple myeloma (2024), published in Haematologica
Osteocytes and Paget's Disease of Bone (2024), published in Current Osteoporosis Reports

The frequent co-authors in their works include Jesús Delgado-Calle, Hayley M. Sabol, Cody Ashby, Noriyoshi Kurihara, and Teresita Bellido.

The main venues for their publications feature journals such as Neoplasia, Cancers, Haematologica, Blood, and Current Osteoporosis Reports.

G. David Roodman has been recognized as a Fellow of the American Association for the Advancement of Science (AAAS) since 2012 and is a member of the Association of American Physicians.

Best Publications

Mechanisms of bone metastasis.

G. David Roodman

2847
Citations
Primer on the metabolic bone diseases and disorders of mineral metabolism

John P. Bilezikian;Roger Bouillon;Thomas Clemens;Juliet Compston

1664
Citations
Osteoclast-like cell formation and its regulation by osteotropic hormones in mouse bone marrow cultures.

N Takahashi;H Yamana;S Yoshiki;G D Roodman

938
Citations
Cell biology of the osteoclast.

G.David Roodman

774
Citations
Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma.

Yazan Alsayed;Hai Ngo;Judith Runnels;Xavier Leleu

572
Citations
Pathogenesis of myeloma bone disease

G. David Roodman;G. David Roodman

544
Citations
Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma

Sun Jin Choi;Jose C. Cruz;Fiona Craig;Hoyeon Chung

477
Citations
Biology of osteoclast activation in cancer.

G. David Roodman

432
Citations
International Myeloma Working Group Recommendations for the Treatment of Multiple Myeloma–Related Bone Disease

Evangelos Terpos;Gareth Morgan;Meletios Athanasios Dimopoulos;Matthew T. Drake

429
Citations
Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study

Noopur Raje;Evangelos Terpos;Wolfgang Willenbacher;Kazuyuki Shimizu

416
Citations
Transforming growth factor beta inhibits formation of osteoclast-like cells in long-term human marrow cultures

C Chenu;J Pfeilschifter;G R Mundy;G D Roodman

406
Citations
Role of Magnetic Resonance Imaging in the Management of Patients With Multiple Myeloma: A Consensus Statement

Meletios A. Dimopoulos;Jens Hillengass;Saad Usmani;Elena Zamagni

399
Citations
Paget disease of bone

G. David Roodman;Jolene J. Windle

396
Citations
Multiple myeloma bone disease: Pathophysiology of osteoblast inhibition.

Nicola Giuliani;Nicola Giuliani;Vittorio Rizzoli;Vittorio Rizzoli;G. David Roodman;G. David Roodman

385
Citations
Macrophage inflammatory protein-1α is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor κB ligand

Je-Ho Han;Sun Jin Choi;Noriyoshi Kurihara;Masanori Koide

384
Citations
1,25-Dihydroxyvitamin D3 causes formation of multinucleated cells with several osteoclast characteristics in cultures of primate marrow.

G D Roodman;K J Ibbotson;B R MacDonald;T J Kuehl

374
Citations
Intracellular fragmentation of bone resorption products by reactive oxygen species generated by osteoclastic tartrate-resistant acid phosphatase.

Jussi M. Halleen;Seija Räisänen;Jari J. Salo;Sakamuri V. Reddy

346
Citations
Excess TGF-β mediates muscle weakness associated with bone metastases in mice

David L Waning;Khalid S Mohammad;Steven Reiken;Wenjun Xie

334
Citations
Antisense inhibition of macrophage inflammatory protein 1-α blocks bone destruction in a model of myeloma bone disease

Sun Jin Choi;Yasuo Oba;Yair Gazitt;Melissa Alsina

318
Citations
Interleukin-6 enhances hypercalcemia and bone resorption mediated by parathyroid hormone-related protein in vivo.

J de la Mata;H L Uy;T A Guise;B Story

316
Citations

Frequent Co-Authors

Irene M. Ghobrial Harvard University

Teresita Bellido University of Arkansas for Medical Sciences

Noopur Raje Harvard University

Guozhi Xiao Southern University of Science and Technology

David W. Dempster Columbia University

Evangelos Terpos National and Kapodistrian University of Athens

Michael P. Whyte Washington University in St. Louis

Allan Lipton Penn State Milton S. Hershey Medical Center

Matthew R. Smith Harvard University

Robin J. Leach The University of Texas Health Science Center at San Antonio

External Links

Personal website of G. David Roodman

If you think any of the details on this page are incorrect, let us know.

Related Online Degrees & Career Pathways

If you're exploring alternatives or complementary paths to traditional MD programs, a range of online healthcare degrees are now more accessible than ever. Flexible learning options can help you start or advance your medical career, often at your own pace and from anywhere.

For those interested in doctor-level practice without extensive residency, a dnp program without clinical hours offers a pathway to advanced nursing leadership roles, focusing primarily on administrative and research skills.

Entry-level roles, such as Licensed Practical Nurse, are now achievable through online lpn programs, which provide foundational medical training and can often be completed quickly.

For those aiming to specialize in mental health, students can choose from the fastest pmhnp program options to become advanced practice psychiatric nurse practitioners.

Alternatively, leadership and administrative careers in healthcare are opened by earning a health administration degree online, preparing graduates for management roles without hands-on clinical requirements.